Diagnostic Substance Manufacturing Business Investment Opportunities in Calgary

Company based in Calgary, Alberta focused on the manufacturing and sales of radiology imaging drugs, with a specific emphasis on barium contrast drugs used by both private and government healthcare facilities in the radiology industry, currently in the pre-revenue stage. - The company is in the process of developing iodine drugs and creating new endohedral fullerene drugs from captured CO2, targeting a market valued at $6.5 billion. - With plans to commence operations this year, the company emphasizes the strategic importance of critical minerals required for the creation of radiology drugs, and it possesses its own resources, enabling it to vertically integrate its radiology drug business. - Aspiring to become the first vertically-integrated North American supplier of medical imaging contrast agents, the company is focused on producing a line of generic and new innovative barium and iodine radiology imaging contrast media products. Additionally, involved in the development of a new carbon fullerene drug for magnetic resonance imaging (MRI). - These products will be supplied to healthcare and imaging facilities. The first contract was signed for USD 1.9M. - Business has 5 Health Canada drug licenses, partnership and exclusive rights to develop endohedral fullerene drugs for the radiology imaging market, and a carbon capture program for future carbon revenue generation.

Company based in Calgary, Alberta focused on the manufacturing and sales of radiology imaging drugs, with a specific emphasis on barium contrast drugs used by both private and government healthcare facilities in the radiology industry, currently in the pre-revenue stage. - The company is in the process of developing iodine drugs and creating new endohedral fullerene drugs from captured CO2, targeting a market valued at $6.5 billion. - With plans to commence operations this year, the company emphasizes the strategic importance of critical minerals required for the creation of radiology drugs, and it possesses its own resources, enabling it to vertically integrate its radiology drug business. - Aspiring to become the first vertically-integrated North American supplier of medical imaging contrast agents, the company is focused on producing a line of generic and new innovative barium and iodine radiology imaging contrast media products. Additionally, involved in the development of a new carbon fullerene drug for magnetic resonance imaging (MRI). - These products will be supplied to healthcare and imaging facilities. The first contract was signed for USD 1.9M. - Business has 5 Health Canada drug licenses, partnership and exclusive rights to develop endohedral fullerene drugs for the radiology imaging market, and a carbon capture program for future carbon revenue generation.